● Recruiting

Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

Condition: HIV · HIV-1 · Sponsor: UBATEC

PhasePhase 4

Planned participants50

Who can joinMale, 18 Years to no upper limit

Healthy volunteersNo

About this study

This single-arm, open label study is aimed to assess efficacy and safety of dolutegravir plus lamivudine as a switch strategy among TGW with HIV receiving suppresive antiretroviral therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Martín Jaume, MD · +54 11 4808-2600 · martinjaume27@gmail.com

José AE Barletta, MD · +54 11 4808-2600 · jbarletta@buenosaires.gob.ar

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital General de Agudos Dr. Juan A. Fernández, Infectious Diseases Division

Buenos Aires, Buenos Aires F.D., Argentina

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06967753